Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), driven by a 6.4% increase in its Zacks Consensus Estimate for the fiscal year ending December 2025 over the past three months. This upward revision in earnings estimates, which the Zacks system correlates strongly with near-term stock price movements, indicates an improvement in Bayer's underlying business and positions the stock within the top 20% of Zacks-covered companies, suggesting potential for favorable near-term performance.
Bayer Aktiengesellschaft (BAYRY) has received an upgrade to a Zacks Rank #2 (Buy), a move primarily driven by positive revisions in its earnings estimates. Specifically, the Zacks Consensus Estimate for the fiscal year ending December 2025 has risen by 6.4% over the last three months, placing the company in the top 20% of stocks covered by the Zacks system. According to the methodology described, this upward trend in analyst estimates is a significant leading indicator of potential near-term stock price appreciation, as it often precedes increased buying from institutional investors who adjust their valuation models. However, it is crucial to note that the current consensus EPS forecast for fiscal 2025, at $1.27 per share, remains unchanged from the year-ago reported figure. This indicates that while the sentiment among analysts has improved recently, the outlook is for flat year-over-year earnings growth, suggesting the positive signal is based on improving momentum rather than a forecast for fundamental acceleration.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
